Single Technology Appraisal (STA)

Dapagliflozin in combination therapy for the treatment of type 2 diabetes
Appraisal consultation document [ID427]

Comments from National Diabetes Nurse Consultant Group

Has all relevant evidence been taken into account	Yes	
Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?	Yes	
Comments		
3.48 – Dapagliflozin dominate DPPIV inhibitors in terms of cost- unclear why the recommendations is being made not to recommend as the analysis shows that it dominates DPPIV inhibitors for a cost perspective and as not as expensive as GLP-1 or some insulin options therefore will not be of any greater expense than many current therapy choices.		
Are the provisional recommendations sound and a suitable basis for guidance to the NHS?	NO	
1.1 Unclear why the recommendations not to recommend has been made as this new class of medication gives another option for people with type 2 diabetes who are refusing an injectable therapy and it has proven benefits as an add on to people with type 2 diabetes on insulin		
Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of gender, race, disability, age, sexua orientation, religion or belief?		No